Taysha Gene Therapies (TSHA) Payables (2020 - 2026)

Taysha Gene Therapies has reported Payables for 7 years, with the latest figure at $4.6 million in Q1 2026.

• Quarterly Payables rose 5.5% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 5.5% YoY) and the FY2025 annual result came in at $6.3 million, up 74.69% from the prior year.
• Payables declined to $4.6 million in Q1 2026 per TSHA's latest filing, from $6.3 million in the prior quarter.
• Over five years, Payables peaked at $148.1 million in Q3 2023 and troughed at $3.6 million in Q4 2024.
• A 5-year average of $17.8 million and a median of $8.7 million in 2024 frame the typical range for Payables.
• The sharpest annual moves came in 2023 and 2024: Payables jumped 870.78% in 2023, then plunged 96.67% in 2024.
• Over 5 years, Payables stood at $10.9 million in 2022, then plunged by 41.84% to $6.4 million in 2023, then plunged by 43.58% to $3.6 million in 2024, then surged by 74.69% to $6.3 million in 2025, then dropped by 27.27% to $4.6 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $4.6 million, $6.3 million, and $5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.